piwik-script

Intern
    Onkologische Forschung

    Ralf C. Bargou: Chair for Translational Oncology

    Summary

    Our group is interested in the development of targeted and personalized therapies for patients with tumors of the lympho-hematopoietic system. We focus on characterization of oncogenic signaling networks in multiple myeloma and their underlying genetic aberrations in a combined functional and genetic approach Complementary to this, we develop T cell engaging therapies for cancer treatment in a variety of cancer entities. Our group translates the knowledge from preclinical research in these fields into the clinic and has initiated a broad early clinical trial program ranging from leukemia to prostate cancer. The program is supported by the central CCC MF Trial Office and is conducted in the Early Clinical Trials Unit (ECTU) of the CCC MF.

    Recent Publications

    Müller E, Bauer S, Stühmer T, Mottok A, Scholz C, Steinbrunn T, Brünnert D, Brandl A, Schraud H, Kreßmann S, Beilhack A, Andreas Rosenwald A, Bargou R, and Chatterjee M. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. Leukemia, 2017, Apr;31(4):922-933.

    Goebeler M-E, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt D, Scheele J, Baeuerle PA, Leo E, and Bargou RC. Bispecific T-Cell Engager (BiTE®) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase 1 Study. J. Clin. Oncol., 2016 Apr 1;34(10):1104-11.

    Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst H-A, Ritgen M, Brüggemann M, Wessiepe D, Holland C, Noemi Mergen, Einsele H, Hoelzer D, Bargou RC. A Phase 2 Trial of the Anti-CD19 (BiTE®) Blinatumomab Shows Haematological and Molecular Remissions in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia. J. Clin. Oncol., 2014, Dec 20;32(36):4134-40.

    Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011 Jun 20;29(18):2493-8.

    Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008 Aug 15;321(5891):974-7.  

    Kontakt

    Comprehensive Cancer Center Mainfranken
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin
    Campus Medizin